ethyl 4-phenoxynicotinate | 1338467-97-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 4-phenoxynicotinate
• 英文别名: ethyl 4-phenoxypyridine-3-carboxylate
• CAS: 1338467-97-2
• 化学式: C₁₄H₁₃NO₃
• 分子量: 243.262
• InChiKey: IQSRVJJAWABDFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-phenoxynicotinate 在 草酰氯 、 水 、 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 生成 4-Phenoxypyridine-3-carbonyl chloride
  参考文献：
  名称：

  Design, Synthesis, and Antidiabetic Activity of 4-Phenoxynicotinamide and 4-Phenoxypyrimidine-5-carboxamide Derivatives as Potent and Orally Efficacious TGR5 Agonists

  摘要：

  4-Phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists are reported. Several 4-phenoxynicotinamide derivatives were found to activate human and mouse TGR5 (hTGR5 and mTGR5) with EC50 values in the low nanomolar range. Compound 23g, with an EC50 value of 0.72 nM on hTGR5 and an EC50 value of 6.2 nM on mTGR5, was selected for further in vivo efficacy studies. This compound exhibited a significant dose-dependent glucagon-like peptide-1 (GLP-1) secretion effect. A single oral dose of 23g (50 mg/kg) significantly reduced blood glucose levels in db/db mice and caused a 49% reduction in the area under the blood glucose curve (AUC)(0-120) (min) following an oral glucose tolerance test (OGTT) in imprinting control region (ICR) mice. However, 23g stimulated gallbladder filling, which might result in side effects to the gallbladder.

  DOI：

  10.1021/jm301071h
• 作为产物：
  描述：

  4-氯烟酰氯化物 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 3.0h， 生成 ethyl 4-phenoxynicotinate
  参考文献：
  名称：

  Design, Synthesis, and Antidiabetic Activity of 4-Phenoxynicotinamide and 4-Phenoxypyrimidine-5-carboxamide Derivatives as Potent and Orally Efficacious TGR5 Agonists

  摘要：

  4-Phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists are reported. Several 4-phenoxynicotinamide derivatives were found to activate human and mouse TGR5 (hTGR5 and mTGR5) with EC50 values in the low nanomolar range. Compound 23g, with an EC50 value of 0.72 nM on hTGR5 and an EC50 value of 6.2 nM on mTGR5, was selected for further in vivo efficacy studies. This compound exhibited a significant dose-dependent glucagon-like peptide-1 (GLP-1) secretion effect. A single oral dose of 23g (50 mg/kg) significantly reduced blood glucose levels in db/db mice and caused a 49% reduction in the area under the blood glucose curve (AUC)(0-120) (min) following an oral glucose tolerance test (OGTT) in imprinting control region (ICR) mice. However, 23g stimulated gallbladder filling, which might result in side effects to the gallbladder.

  DOI：

  10.1021/jm301071h

文献信息

• NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I
  申请人：Braje Wilfried

  公开号：US20110245232A1

  公开（公告）日：2011-10-06

  The present invention relates to small molecule potentiators of metabotropic receptors, in particular of the mGlu2 receptor. The present invention also relates to the use of these compounds for the prevention or treatment of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The present invention thus provides compounds of formula I wherein X 2 is N or C—R 2 , X 3 is N or C—R 3 , X 4 is N or C—R 4 provided that none or one of X 2 , X 3 or X 4 is N; Y 1 is N, C or C—R 5 , Y 2 is N, C or C—R 6 , Y 3 is N, C or C—R 7 , Y 4 is N, C or C—R 8 provided that only the moiety Y 1 , Y 2 , Y 3 or Y 4 to which Z is bound is C and further provided at most one of Y 1 , Y 2 , Y 3 or Y 4 is N; Z is O, S, S(O), S(O) 2 or NR Z ; Q is CH 2 or CH 2 CH 2 , where one or two of the hydrogen atoms in CH 2 or CH 2 CH 2 may be replaced by halogen, C 1 -C 4 -alkyl or C 1 -C 4 -haloalkyl; R 1 is inter alia hydrogen, halogen, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -alkoxy, C 1 -C 4 -haloalkoxy, C 3 -C 8 -cycloalkyl, a radical NR 1a R 1b , C-bound 3- to 7-membered, saturated heterocyclyl having 1 or 2 nitrogen atoms and 0 or 1 heteroatoms, selected from O and S, as ring members, aryl, aryl-CH 2 , aryloxy, hetaryl, hetaryloxy or hetaryl-CH 2 , wherein the heterocyclyl, aryl and hetaryl rings ring in the last six radicals themselves are unsubstituted or carry 1, 2, 3, 4 or 5 identical or different radicals R 1c ; R 2 , R 3 and R 4 are, inter alia, selected from hydrogen, halogen, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, phenyl, C 1 -C 4 -haloalkoxy, a radical (CH 2 ) n NR′R″; R 5 , R 6 , R 7 , R 8 are, independently of each other, selected from hydrogen, halogen, etc.; R a is C 3 -C 6 -cycloalkyl, C 1 -C 6 -haloalkyl or C 1 -C 6 -alkyl, which is unsubstituted or carries one radical selected from C 1 -C 4 -alkoxy, C 1 -C 4 -haloalkoxy and a radical NR a1 R a2 , R b is hydrogen, halogen or C 1 -C 4 -alkyl; and the N-oxides and the pharmaceutically acceptable salts thereof.

  本发明涉及代谢型受体的小分子增强剂，特别是mGlu2受体的增强剂。本发明还涉及这些化合物的使用，用于预防或治疗与谷氨酸功能障碍有关的神经和精神障碍以及代谢型谷氨酸受体参与的疾病。因此，本发明提供了式I的化合物，其中X2为N或C—R2，X3为N或C—R3，X4为N或C—R4，但X2、X3或X4中没有或只有一个为N；Y1为N、C或C—R5，Y2为N、C或C—R6，Y3为N、C或C—R7，Y4为N、C或C—R8，但只有Y1、Y2、Y3或Y4中的一个Y与Z相连的基团为C且最多只有一个Y为N；Z为O、S、S(O)、S(O)2或NRZ；Q为CH2或 ，其中 或 中的一个或两个氢原子可以被卤素、C1-C4烷基或C1-C4卤代烷基取代；R1为氢、卤素、C1-C6烷基、C1-C6卤代烷基、C1-C6烷氧基、C1-C4卤代烷氧基、C3-C8环烷基、基团NR1aR1b、C-连接的3-至7-成员饱和杂环基，其中有1或2个氮原子和0或1个杂原子，选自O和S作为环成员，芳基、芳基- 、芳氧基、杂芳基、杂芳氧基或杂芳基- ，其中在最后六个基团中的杂环基、芳基和杂芳基环本身未取代或携带1、2、3、4或5个相同或不同的基团R1c；R2、R3和R4等，选自氢、卤素、C1-C4烷基、C1-C4卤代烷基、C3-C6环烷基、C1-C4烷氧基、C1-C4烷氧基-C1-C4-烷基、苯基、C1-C4卤代烷氧基、基团( )nNR′R″；R5、R6、R7和R8独立地选自氢、卤素等；Ra为C3-C6环烷基、C1-C6卤代烷基或C1-C6烷基，未取代或携带选自C1-C4烷氧基、C1-C4卤代烷氧基和基团NRa1Ra2的一个基团；Rb为氢、卤素或C1-C4烷基；以及其N-氧化物和药学上可接受的盐。
• Small molecule potentiators of metabotropic glutamate receptors I
  申请人：Braje Wilfried

  公开号：US08664214B2

  公开（公告）日：2014-03-04

  The present invention relates to small molecule potentiators of metabotropic receptors, in particular of the mGlu2 receptor. The present invention also relates to the use of these compounds for the prevention or treatment of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The present invention thus provides compounds of formula I and variables defined herein.

  本发明涉及代谢型受体的小分子增强剂，特别是mGlu2受体的增强剂。本发明还涉及使用这些化合物预防或治疗与谷氨酸功能障碍有关的神经和精神障碍以及代谢型谷氨酸受体参与的疾病。因此，本发明提供了公式I和在此定义的变量的化合物。
• US8664214B2
  申请人：——

  公开号：US8664214B2

  公开（公告）日：2014-03-04